The bioengineered protein drugs market is experiencing a paradigm shift, with pharmaceutical and biotech companies leveraging advanced biopharmaceuti ...

MeiraGTx (Nasdaq: MGTX) has entered into a strategic partnership with artificial intelligence firm Hologen to accelerate the ...

Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

Diamyd Medical, in collaboration with Mainly AI and ASSET partners, highlights meaningful progress in AI-driven screening and risk prediction for Type 1 Diabetes at the Advanced Technologies & Treatme ...

The latest HPRA inspection in February 2025 was highly successful-both QC licences were renewed, and viral vector manufacturing was added to the MIA (IMP) licence. This means the Shannon site can ...

Explore why Recursion Pharmaceuticals' AI-driven drug discovery faces challenges in revenue growth, governance, and investor ...

Life science companies developing bird flu vaccines are gaining attention as the avian influenza subtype H5N1 becomes an ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Japanese drugmaker Ono (TYO: 4528) has entered into a license agreement with USA-based Ionis Pharmaceuticals (Nasdaq: IONS) ...

Sanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.

Shares of Danish biotech Zealand Pharma (Nasdaq: ZEAL) were up 30% at 635.50 kroner by early afternoon, on news of a potentially lucrative licensing deal with Swiss pharm giant Roche (ROG: SIX). Under ...

US biopharma Viking Therapeutics developing therapies for metabolic and endocrine disorders, closed Tuesday’s trading 5% ...